| Similar Articles |
|---|
 |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options.   |
Pharmaceutical Executive
March 1, 2013
Ken Getz |
Building Clinical Trial Awareness for Patients: Why Not Try the Pharmacist? The author explains how building a stakeholder outreach agenda around the community pharmacist can lead to a better outcome in managing the complex ins and outs of a trial protocol. |
Managed Care
July 2003
Thomas Morrow |
Drug-Eluting Stents To Transform Cardiovascular Medicine By reducing restenosis, these devices will save managed care money. |
Managed Care
June 2006
Tom Pope |
Hard to Curb Overuse of Drug-Eluting Stents Health plans find themselves paying for the latest and greatest stent without any control over usage. Even bare-metal stents may be overused. |
American Family Physician
August 1, 2004
Wiviott & Braunwald |
Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: Part II. Coronary Revascularization, Hospital Discharge, and Post-Hospital Care In patients hospitalized with UA/NSTEMI, one of the most important decisions is the early strategy of care regarding coronary angiography and revascularization. |
AskMen.com
Richard Stevens |
Participating In Clinical Trials Check out what participating in clinical trials involves and how you can join a study. You may even make some cash in the process. |
Bio-IT World
March 10, 2003
Spink & Blumenstiel |
Getting IT Right Applying information technology to trials can boost productivity. Here's a strategic framework for going e-clinical. |
Bio-IT World
August 2005
Ellen H. Julian |
Tech Expertise Singles Out Outsourcers Biopharmaceutical companies are flocking to consultants, outsourcers, and staffing firms to help with discrete clinical trial processes to gain access to advanced technologies and reduce the drain on already-scarce IT resources. |
The Motley Fool
October 31, 2006
Michael P. Cecil |
An Opening for Plavix New data suggesting problems with drug-eluting stents may translate into more sales of the blood thinner Plavix and fewer sales of the stents. Investors, take note. |
